tiotropium bromide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
atropine derivatives 2677 186691-13-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tiotropium bromide hydrate
  • tiotropium
  • respimat
  • tiotropium bromide
  • tiotropium bromide monohydrate
  • spiriva
  • tiotropiumbromide
A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.
  • Molecular weight: 392.51
  • Formula: C19H22NO4S2
  • CLOGP: -1.71
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 59.06
  • ALOGS: -4.44
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mcg Inhal.powder
5 mcg Inhal.solution

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 74 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 2.50 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 32 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12.60 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.28 % Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 30, 2004 FDA BOEHRINGER INGELHEIM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incorrect route of product administration 14783.68 38.84 2400 4822 2936 2347927
Dyspnoea 2060.86 38.84 872 6350 77861 2273002
Product quality issue 1372.51 38.84 393 6829 10436 2340427
Asthma 1359.95 38.84 394 6828 10920 2339943
Chronic obstructive pulmonary disease 1247.20 38.84 333 6889 6744 2344119
Drug ineffective 818.45 38.84 513 6709 101111 2249752
Cough 766.40 38.84 340 6882 32777 2318086
Obstructive airways disorder 668.80 38.84 147 7075 1226 2349637
Wheezing 572.67 38.84 178 7044 6206 2344657
Pneumonia 385.89 38.84 246 6976 49050 2301813
Dry mouth 363.36 38.84 135 7087 8118 2342745
Blood count abnormal 361.22 38.84 99 7123 2183 2348680
Dysphonia 335.70 38.84 119 7103 6245 2344618
Productive cough 301.64 38.84 105 7117 5216 2345647
Therapeutic product effect incomplete 294.12 38.84 124 7098 10407 2340456
Urinary retention 294.11 38.84 94 7128 3573 2347290
Chest discomfort 249.32 38.84 122 7100 14473 2336390
Vision blurred 199.06 38.84 105 7117 14563 2336300
Lung neoplasm malignant 172.16 38.84 60 7162 2982 2347881
Pulmonary mass 152.80 38.84 49 7173 1877 2348986
Sputum discoloured 149.82 38.84 43 7179 1123 2349740
Product physical issue 146.73 38.84 41 7181 969 2349894
Throat irritation 123.04 38.84 54 7168 4976 2345887
Ageusia 111.45 38.84 39 7183 1959 2348904
Choking 109.28 38.84 36 7186 1502 2349361
Total lung capacity increased 104.77 38.84 16 7206 4 2350859
Dyspnoea exertional 101.05 38.84 49 7173 5671 2345192
Oropharyngeal pain 100.90 38.84 62 7160 11456 2339407
Increased upper airway secretion 100.78 38.84 28 7194 647 2350216
Lower respiratory tract infection 100.47 38.84 48 7174 5376 2345487
Off label use 98.10 38.84 137 7085 73461 2277402
Restrictive pulmonary disease 96.81 38.84 21 7201 162 2350701
Constipation 90.24 38.84 74 7148 21555 2329308
Bronchitis 88.63 38.84 61 7161 13653 2337210
Eosinophilia 86.19 38.84 36 7186 2934 2347929
Lung disorder 85.65 38.84 45 7177 6167 2344696
Dizziness 82.28 38.84 112 7110 58553 2292310
Fall 81.84 38.84 100 7122 46999 2303864
Upper-airway cough syndrome 81.39 38.84 26 7196 982 2349881
Condition aggravated 79.74 38.84 82 7140 31897 2318966
Respiration abnormal 79.66 38.84 23 7199 613 2350250
Malaise 79.28 38.84 107 7115 55478 2295385
Chest pain 79.07 38.84 77 7145 28060 2322803
Bronchiectasis 78.47 38.84 25 7197 936 2349927
Dry throat 73.24 38.84 24 7198 984 2349879
Rhinorrhoea 72.44 38.84 43 7179 7457 2343406
Laryngeal pain 72.07 38.84 24 7198 1035 2349828
Swollen tongue 71.65 38.84 38 7184 5305 2345558
Tremor 70.48 38.84 63 7159 20598 2330265
Oedema peripheral 70.47 38.84 67 7155 23696 2327167
Eosinophil count increased 70.46 38.84 24 7198 1110 2349753
Nasal congestion 70.06 38.84 41 7181 6925 2343938
Gastrooesophageal reflux disease 69.70 38.84 45 7177 9050 2341813
Glaucoma 69.67 38.84 28 7194 2067 2348796
Forced expiratory volume decreased 69.55 38.84 20 7202 525 2350338
Throat tightness 69.42 38.84 35 7187 4401 2346462
Rash 67.79 38.84 103 7119 59455 2291408
Reversible airways obstruction 67.43 38.84 12 7210 26 2350837
Tachycardia 63.96 38.84 54 7168 16355 2334508
Emphysema 63.66 38.84 22 7200 1063 2349800
Cataract 62.67 38.84 36 7186 5872 2344991
Pharyngeal oedema 61.91 38.84 30 7192 3463 2347400
Loss of personal independence in daily activities 60.75 38.84 34 7188 5277 2345586
Bronchospasm 59.78 38.84 28 7194 2996 2347867
Respiratory failure 57.88 38.84 47 7175 13481 2337382
Palpitations 57.74 38.84 51 7171 16405 2334458
Myocardial infarction 57.10 38.84 54 7168 18959 2331904
Heart rate increased 57.07 38.84 43 7179 11062 2339801
Abnormal loss of weight 56.67 38.84 18 7204 667 2350196
Aphonia 56.12 38.84 21 7201 1278 2349585
Blood test abnormal 55.83 38.84 21 7201 1297 2349566
Depression 52.50 38.84 62 7160 28070 2322793
Oral discomfort 52.44 38.84 20 7202 1283 2349580
Blood immunoglobulin E increased 51.12 38.84 14 7208 306 2350557
Dysgeusia 50.82 38.84 36 7186 8423 2342440
Nervousness 50.75 38.84 30 7192 5159 2345704
Macular degeneration 50.04 38.84 19 7203 1204 2349659
Dysuria 49.94 38.84 27 7195 3914 2346949
Asthma-chronic obstructive pulmonary disease overlap syndrome 48.62 38.84 8 7214 8 2350855
Pruritus 47.90 38.84 74 7148 43266 2307597
Hypoacusis 47.73 38.84 25 7197 3400 2347463
Chronic sinusitis 47.37 38.84 15 7207 550 2350313
Hypertension 47.28 38.84 58 7164 27303 2323560
Mycobacterium avium complex infection 47.22 38.84 14 7208 410 2350453
Death 46.91 38.84 105 7117 81363 2269500
Medication error 46.14 38.84 30 7192 6101 2344762
Frustration tolerance decreased 45.45 38.84 16 7206 817 2350046
Eosinophil count abnormal 45.17 38.84 9 7213 43 2350820
Eye pain 44.51 38.84 27 7195 4864 2345999
Dry eye 44.35 38.84 25 7197 3931 2346932
Pulmonary thrombosis 44.18 38.84 17 7205 1117 2349746
Headache 43.56 38.84 101 7121 80078 2270785
Middle insomnia 43.17 38.84 18 7204 1459 2349404
Swelling face 42.76 38.84 34 7188 9459 2341404
Oxygen saturation decreased 42.62 38.84 31 7191 7555 2343308
Product prescribing error 42.37 38.84 22 7200 2938 2347925
Hypersensitivity 42.36 38.84 51 7171 23542 2327321
Oral pain 42.28 38.84 23 7199 3374 2347489
Stomatitis 42.08 38.84 34 7188 9676 2341187
Nasal polyps 41.82 38.84 11 7211 205 2350658
Therapeutic response decreased 41.79 38.84 30 7192 7165 2343698
Weight decreased 40.93 38.84 55 7167 28316 2322547
Hypoxia 40.91 38.84 28 7194 6199 2344664
Upper respiratory tract infection 40.51 38.84 32 7190 8819 2342044
Visual impairment 40.36 38.84 36 7186 11719 2339144
Candida infection 40.12 38.84 21 7201 2852 2348011
Visual acuity reduced 40.05 38.84 26 7196 5272 2345591
Drug hypersensitivity 39.92 38.84 71 7151 46572 2304291
Dysphagia 39.63 38.84 37 7185 12768 2338095
Cardiac failure congestive 39.55 38.84 41 7181 16060 2334803
Glossitis 39.38 38.84 13 7209 545 2350318
Breath sounds abnormal 39.34 38.84 14 7208 738 2350125
Acute respiratory failure 39.01 38.84 21 7201 3017 2347846
Asthmatic crisis 38.95 38.84 11 7211 270 2350593

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Incorrect route of product administration 6402.51 40.30 1161 4572 2304 1738744
Chronic obstructive pulmonary disease 1803.16 40.30 454 5279 5499 1735549
Dyspnoea 1441.77 40.30 651 5082 51408 1689640
Asthma 838.55 40.30 239 5494 4665 1736383
Urinary retention 604.89 40.30 190 5543 5205 1735843
Cough 593.62 40.30 262 5471 18935 1722113
Drug ineffective 578.09 40.30 384 5349 63417 1677631
Product quality issue 561.90 40.30 185 5548 5908 1735140
Obstructive airways disorder 523.93 40.30 121 5612 953 1740095
Wheezing 464.00 40.30 146 5587 4007 1737041
Pneumonia 428.53 40.30 283 5450 45899 1695149
Dry mouth 364.99 40.30 120 5613 3793 1737255
Productive cough 267.24 40.30 93 5640 3498 1737550
Blood count abnormal 230.23 40.30 67 5666 1390 1739658
Chest discomfort 215.58 40.30 97 5636 7234 1733814
Therapeutic product effect incomplete 195.62 40.30 83 5650 5365 1735683
Condition aggravated 181.32 40.30 124 5609 21026 1720022
Sputum discoloured 175.76 40.30 46 5687 631 1740417
Lung neoplasm malignant 171.63 40.30 65 5668 3114 1737934
Dyspnoea exertional 171.61 40.30 70 5663 4091 1736957
Lower respiratory tract infection 152.71 40.30 63 5670 3788 1737260
Dysuria 141.97 40.30 59 5674 3613 1737435
Atrial fibrillation 135.06 40.30 91 5642 15020 1726028
Vision blurred 132.80 40.30 73 5660 8350 1732698
Respiratory failure 128.78 40.30 87 5646 14418 1726630
Emphysema 118.98 40.30 39 5694 1212 1739836
Benign prostatic hyperplasia 103.07 40.30 36 5697 1362 1739686
Dysphonia 101.06 40.30 46 5687 3509 1737539
Bronchial obstruction 100.48 40.30 24 5709 220 1740828
Cardiac failure 96.36 40.30 69 5664 12533 1728515
Oxygen saturation decreased 94.43 40.30 51 5682 5624 1735424
Death 91.84 40.30 169 5564 87274 1653774
Chest pain 89.91 40.30 80 5653 19834 1721214
Bronchiectasis 89.36 40.30 26 5707 537 1740511
Pulmonary mass 84.45 40.30 31 5702 1356 1739692
Off label use 84.11 40.30 105 5628 38466 1702582
Forced expiratory volume decreased 82.49 40.30 23 5710 405 1740643
Bronchospasm 78.90 40.30 33 5700 2049 1738999
Bronchopulmonary aspergillosis allergic 77.23 40.30 15 5718 43 1741005
Asthma-chronic obstructive pulmonary disease overlap syndrome 77.08 40.30 13 5720 10 1741038
Granulomatous rosacea 76.15 40.30 12 5721 2 1741046
Throat irritation 73.93 40.30 30 5703 1724 1739324
N-terminal prohormone brain natriuretic peptide abnormal 69.66 40.30 11 5722 2 1741046
Lung disorder 68.80 40.30 40 5693 5079 1735969
Pulmonary function test decreased 68.15 40.30 20 5713 426 1740622
Myocardial infarction 65.69 40.30 78 5655 27096 1713952
Hypoxia 65.67 40.30 41 5692 5922 1735126
Sleep disorder 63.37 40.30 35 5698 4028 1737020
Oedema peripheral 63.33 40.30 59 5674 15491 1725557
Left ventricular dilatation 63.21 40.30 13 5720 54 1740994
Hangover 62.91 40.30 16 5717 194 1740854
Brain natriuretic peptide abnormal 61.23 40.30 11 5722 17 1741031
Sputum increased 59.91 40.30 15 5718 170 1740878
Fractured coccyx 58.47 40.30 11 5722 25 1741023
Constipation 57.42 40.30 55 5678 14945 1726103
Cardiac failure chronic 56.79 40.30 19 5714 629 1740419
Nasal congestion 54.64 40.30 29 5704 3082 1737966
Swollen tongue 54.53 40.30 28 5705 2780 1738268
Fall 54.34 40.30 71 5662 27143 1713905
Blood test abnormal 53.76 40.30 20 5713 908 1740140
Nasal polyps 53.59 40.30 14 5719 190 1740858
Blood thyroid stimulating hormone abnormal 53.23 40.30 11 5722 47 1741001
Urticaria 52.85 40.30 48 5685 12193 1728855
Oxygen saturation increased 52.77 40.30 10 5723 24 1741024
Pulmonary arterial pressure abnormal 52.77 40.30 10 5723 24 1741024
Malaise 52.73 40.30 73 5660 29492 1711556
Aphonia 52.28 40.30 17 5716 514 1740534
Breath sounds abnormal 50.10 40.30 17 5716 588 1740460
Dizziness 49.91 40.30 77 5656 34284 1706764
Lung hyperinflation 49.17 40.30 11 5722 73 1740975
Bronchitis 49.10 40.30 33 5700 5399 1735649
Laryngeal pain 48.45 40.30 17 5716 651 1740397
Hepatic haematoma 47.26 40.30 11 5722 89 1740959
Ageusia 46.71 40.30 21 5712 1553 1739495
Gastrooesophageal reflux disease 46.29 40.30 30 5703 4617 1736431
Electrocardiogram QRS complex abnormal 46.15 40.30 10 5723 56 1740992
Eosinophilia 45.90 40.30 27 5706 3500 1737548
Acute respiratory failure 44.94 40.30 25 5708 2915 1738133
Hyperkalaemia 43.88 40.30 37 5696 8510 1732538
Overdose 43.74 40.30 50 5683 16651 1724397
Type 2 diabetes mellitus 43.17 40.30 21 5712 1857 1739191
Eosinophil count increased 42.56 40.30 19 5714 1382 1739666
Cardiac failure congestive 42.17 40.30 47 5686 15223 1725825
Vital capacity decreased 42.07 40.30 9 5724 47 1741001
Aortic aneurysm 41.56 40.30 17 5716 996 1740052
Pneumothorax 41.29 40.30 23 5710 2689 1738359
Bronchial hyperreactivity 40.78 40.30 11 5722 170 1740878
Respiratory disorder 40.69 40.30 24 5709 3125 1737923
Hyperkaliuria 40.65 40.30 7 5726 7 1741041
Visual impairment 40.61 40.30 31 5702 6187 1734861

Pharmacologic Action:

SourceCodeDescription
ATC R03AL06 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03AL10 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
ADRENERGICS, INHALANTS
Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
ATC R03BB04 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Anticholinergics
ATC R03BB54 RESPIRATORY SYSTEM
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
Anticholinergics
FDA EPC N0000175574 Anticholinergic
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D001993 Bronchodilator Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D019141 Respiratory System Agents
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:35523 bronchodilator agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Chronic bronchitis indication 63480004 DOID:6132
Pulmonary emphysema indication 87433001
Asthma indication 195967001 DOID:2841
Bronchospasm Prevention with COPD indication
Chronic Obstructive Pulmonary Disease with Bronchospasms indication
Impaired renal function disorder contraindication 197663003
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Angle-closure glaucoma contraindication 392291006 DOID:13550
Cardiovascular event risk contraindication 395112001

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 13.97 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.018MG BASE/INH SPIRIVA BOEHRINGER INGELHEIM N021395 Jan. 30, 2004 RX POWDER INHALATION 6908928 Sept. 24, 2021 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.018MG BASE/INH SPIRIVA BOEHRINGER INGELHEIM N021395 Jan. 30, 2004 RX POWDER INHALATION 6908928 Sept. 24, 2021 TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
EQ 0.018MG BASE/INH SPIRIVA BOEHRINGER INGELHEIM N021395 Jan. 30, 2004 RX POWDER INHALATION 7070800 Jan. 22, 2022 FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8044046 Nov. 10, 2023 TREATMENT OF COPD
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 7220742 May 12, 2025 TREATMENT OF RESPIRATORY COMPLAINTS
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION 8034809 May 12, 2025 TREATMENT OF COPD
EQ 0.018MG BASE/INH SPIRIVA BOEHRINGER INGELHEIM N021395 Jan. 30, 2004 RX POWDER INHALATION 8022082 Jan. 19, 2026 ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.00125MG BASE/INH SPIRIVA RESPIMAT BOEHRINGER INGELHEIM N021936 Sept. 15, 2015 RX SPRAY, METERED INHALATION Feb. 15, 2020 NEW PATIENT POPULATION
EQ 0.0025MG BASE/INH SPIRIVA RESPIMAT BOEHRINGER INGELHEIM N021936 Sept. 24, 2014 RX SPRAY, METERED INHALATION Feb. 15, 2020 NEW PATIENT POPULATION
EQ 0.00125MG BASE/INH SPIRIVA RESPIMAT BOEHRINGER INGELHEIM N021936 Sept. 15, 2015 RX SPRAY, METERED INHALATION Aug. 15, 2020 PEDIATRIC EXCLUSIVITY
EQ 0.0025MG BASE/INH SPIRIVA RESPIMAT BOEHRINGER INGELHEIM N021936 Sept. 24, 2014 RX SPRAY, METERED INHALATION Aug. 15, 2020 PEDIATRIC EXCLUSIVITY
EQ 0.0025MG BASE/INH STIOLTO RESPIMAT BOEHRINGER INGELHEIM N206756 May 21, 2015 RX SPRAY, METERED INHALATION Oct. 5, 2021 INFORMATION ADDED TO THE LABELING TO DESCRIBE FIXED-DOSE COMBINATION OF TIOTROPIUM BROMIDE AND OLODATEROL TO INCLUDE REDUCTION OF COPD EXACERBATIONS

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 11.10 WOMBAT-PK CHEMBL
Muscarinic acetylcholine receptor M5 GPCR Ki 11 WOMBAT-PK
Muscarinic acetylcholine receptor M4 GPCR Ki 11 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 11 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 11 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 9.80 CHEMBL
Muscarinic acetylcholine receptor M3 GPCR Ki 9.52 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 9.82 CHEMBL

External reference:

IDSource
D000069447 MESH_DESCRIPTOR_UI
4021416 VUID
N0000148830 NUI
C0213771 UMLSCUI
393575 RXNORM
425812008 SNOMEDCT_US
009713 NDDF
31060 MMSL
CHEMBL1182657 ChEMBL_ID
L64SXO195N UNII
411207-31-3 SECONDARY_CAS_RN
0HK PDB_CHEM_ID
DB01409 DRUGBANK_ID
CHEBI:32230 CHEBI
CHEMBL1900528 ChEMBL_ID
CHEMBL3545181 ChEMBL_ID
5487426 PUBCHEM_CID
367 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Spiriva HUMAN PRESCRIPTION DRUG LABEL 1 0597-0075 CAPSULE 18 ug ORAL NDA 19 sections
Spiriva Respimat HUMAN PRESCRIPTION DRUG LABEL 1 0597-0100 SPRAY, METERED 3.12 ug RESPIRATORY (INHALATION) NDA 18 sections
Stiolto Respimat HUMAN PRESCRIPTION DRUG LABEL 2 0597-0155 SPRAY, METERED 3.12 ug RESPIRATORY (INHALATION) NDA 19 sections
Spiriva Respimat HUMAN PRESCRIPTION DRUG LABEL 1 0597-0160 SPRAY, METERED 1.56 ug RESPIRATORY (INHALATION) NDA 18 sections
Spiriva HUMAN PRESCRIPTION DRUG LABEL 1 50090-4414 CAPSULE 18 ug ORAL NDA 17 sections
Spiriva HUMAN PRESCRIPTION DRUG LABEL 1 54868-5109 CAPSULE 18 ug ORAL NDA 18 sections